Ming-Jun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ming-Jun Zhu has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Yu-Tao Wang
13 shared publicationsBin-Bin Hu
Yunnan Academy of Tobacco Agricultural Sciences
11 shared publicationsJie Bu
10 shared publicationsJing-Rong Cheng
Sericultural & Agri-Food Research Institute, Guangdong Academy of Agricultural Sciences, Key Laboratory of Functional Foods, Ministry of Agriculture and Rural Affairs, Guangdong Key Laboratory of Agricultural Products Processing, Guangzhou 510610, China
8 shared publicationsJingrong Cheng
Sericultural & Agri-Food Research Institute, Guangdong Academy of Agricultural Sciences, Key Laboratory of Functional Foods, Ministry of Agriculture and Rural Affairs, Guangdong Key Laboratory of Agricultural Products Processing, Guangzhou 510610, PR China; Guangdong Engineering Center for Biopharmaceuticals, School of Biology and Biological Engineering, South China University of Technology, Guangzhou Higher Education Mega Center, Panyu, Guangzhou 510006, People's Republic of China
7 shared publicationsJing Mai
School of Biology and Biological Engineering, Guangdong Key Laboratory of Fermentation and Enzyme Engineering, South China University of Technology, Guangzhou Higher Education Mega Center, Panyu, Guangzhou 510006, China
5 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 36 (9) , 1-11
Bacillus subtilis DES-59 Modulates Microbial Community Structure and Aroma Formation in Cigar Fermentation to Improve the Quality of Heat-Not-Burn (HnB) Tobacco
Lu-Xin Liang, Ming-Jun Zhu , and Lu Zhao. J. Microbiol. Biotechnol. 2026;36:1-11. https://doi.org/10.4014/jmb.2605.05012
- 2 September 2026
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 36 (9) , 1-11
Open AccessBacillus subtilis DES-59 Modulates Microbial Community Structure and Aroma Formation in Cigar Fermentation to Improve the Quality of Heat-Not-Burn (HnB) Tobacco
Lu-Xin Liang, Ming-Jun Zhu , and Lu Zhao. J. Microbiol. Biotechnol. 2026;36:1-11. https://doi.org/10.4014/jmb.2605.05012
- 4 June 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (23) , 10531-10541
Alkaline Biochar Promoted Stable and Efficient Thermophilic Hydrogen Production from Lignocellulose by Restoring Coculture System Homeostasis
- 4 June 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (23) , 10531-10541
Alkaline Biochar Promoted Stable and Efficient Thermophilic Hydrogen Production from Lignocellulose by Restoring Coculture System Homeostasis
- 13 April 2026
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- p. 1-14
Expanding the operational window of consolidated bioprocessing hydrogen production from non-detoxified alkali-pretreated tobacco stalks via microbial co-cultivation
This study investigated the feasibility of producing biohydrogen from non-detoxified alkali-pretreated tobacco stalks through separate hydrolysis and fermentation (SHF) and consolidated bioprocessing (CBP). In SHF, Thermoanaerobacterium thermosaccharolyticum MJ2 produced 215.26 ± 49.61 mM hydrogen from non-detoxified enzymatic hydrolysates, demonstrating substantial fermentative capacity under pretreatment-derived inhibitory stress. In CBP, hydrogen production by Acetivibrio thermocellus DSM1313 alone was severely inhibited by 90.71% when non-detoxified stalks were used, whereas co-cultivation with MJ2 markedly alleviated this inhibition and restored hydrogen production to 91.34% of the level obtained from detoxified stalks. To further characterize the tolerance of the co-culture system, a gradient of pretreatment liquor (0–100%, v/v) was introduced as an inhibitory stress factor. Kinetic analysis using the modified Gompertz model showed that the co-culture achieved a maximum hydrogen potential of 125.91 ± 0.54 mM at 40% (v/v) pretreatment liquor, corresponding to a 44.27% increase over the control. A hormetic effect was observed at 20% liquor concentration, whereas a critical threshold was identified at 60%, where hydrogen production sharply declined due to growth arrest of the primary cellulose degrader, DSM1313. These results demonstrate that microbial co-cultivation effectively enhances hydrogen production performance under non-detoxified conditions and expands the operational window of CBP using alkali-pretreated tobacco stalks. The beneficial effect is clearly supported at the functional level and suggests an improved consortium tolerance to pretreatment-derived inhibitory stress.
- 13 April 2026
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- p. 1-14
Expanding the operational window of consolidated bioprocessing hydrogen production from non-detoxified alkali-pretreated tobacco stalks via microbial co-cultivation
This study investigated the feasibility of producing biohydrogen from non-detoxified alkali-pretreated tobacco stalks through separate hydrolysis and fermentation (SHF) and consolidated bioprocessing (CBP). In SHF, Thermoanaerobacterium thermosaccharolyticum MJ2 produced 215.26 ± 49.61 mM hydrogen from non-detoxified enzymatic hydrolysates, demonstrating substantial fermentative capacity under pretreatment-derived inhibitory stress. In CBP, hydrogen production by Acetivibrio thermocellus DSM1313 alone was severely inhibited by 90.71% when non-detoxified stalks were used, whereas co-cultivation with MJ2 markedly alleviated this inhibition and restored hydrogen production to 91.34% of the level obtained from detoxified stalks. To further characterize the tolerance of the co-culture system, a gradient of pretreatment liquor (0–100%, v/v) was introduced as an inhibitory stress factor. Kinetic analysis using the modified Gompertz model showed that the co-culture achieved a maximum hydrogen potential of 125.91 ± 0.54 mM at 40% (v/v) pretreatment liquor, corresponding to a 44.27% increase over the control. A hormetic effect was observed at 20% liquor concentration, whereas a critical threshold was identified at 60%, where hydrogen production sharply declined due to growth arrest of the primary cellulose degrader, DSM1313. These results demonstrate that microbial co-cultivation effectively enhances hydrogen production performance under non-detoxified conditions and expands the operational window of CBP using alkali-pretreated tobacco stalks. The beneficial effect is clearly supported at the functional level and suggests an improved consortium tolerance to pretreatment-derived inhibitory stress.
- 21 February 2026
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 141 (5) , 339-349
Enhancing sensory quality of heat-not-burn tobacco via bioaugmentation with Cytobacillus oceanisediminis C4 and amylase
- 21 February 2026
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 141 (5) , 339-349
Enhancing sensory quality of heat-not-burn tobacco via bioaugmentation with Cytobacillus oceanisediminis C4 and amylase
- 15 December 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 376, 124815
Enhanced stability and bioavailability of astaxanthin via piperine co-encapsulation in whey protein fibril- sodium alginate complexes
- 15 December 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 376, 124815
Enhanced stability and bioavailability of astaxanthin via piperine co-encapsulation in whey protein fibril- sodium alginate complexes
- Open Access
Research Progress on the Mechanism of Action and Screening Methods of Probiotics for Lowering Blood Lipid Levels
Hyperlipidemia is one of the most prevalent metabolic disorders worldwide. It is a significant risk factor for a range of cardiovascular diseases, including acute pancreatitis, fatty liver disease, atherosclerosis, and coronary heart disease. In clinical practice, the management of hyperlipidemia is hindered by numerous challenges. One of the critical issues is that traditional lipid-lowering drugs often require long-term or even lifelong administration, potentially inducing a range of adverse effects that compromise patient compliance and therapeutic efficacy. Therefore, there is an urgent need to develop safer and more effective strategies for the prevention and adjunctive treatment of hyperlipidemia with the aim of reducing the risk of disease and over-reliance on medication. Recent studies have revealed a close relationship between hyperlipidemia and related metabolic disorders involving gut microbiota dysbiosis, and the administration of probiotics has been shown to improve lipid metabolism homeostasis. This review summarizes the molecular mechanisms of probiotics in hyperlipidemia treatment and the latest advances in probiotic research on lipid metabolism, enumerates the experimental and clinical applications of probiotic-based therapies, introduces methods for screening and identifying probiotics with lipid-lowering functions, and, for the first time, summarizes the roles of emerging technologies such as functional genomics and in vivo zebrafish-on-a-chip models in studying the lipid-lowering efficacy of probiotics, providing insights for researchers. By facilitating a deeper understanding of the mechanisms whereby probiotics reduce blood lipid levels and furthering the development of multifaceted screening methods, we hope that we can achieve high-throughput and efficient screening of probiotics with lipid-lowering functions, thereby promoting the sustainable, high-quality, and rapid development of the probiotics industry.
Open AccessResearch Progress on the Mechanism of Action and Screening Methods of Probiotics for Lowering Blood Lipid Levels
Hyperlipidemia is one of the most prevalent metabolic disorders worldwide. It is a significant risk factor for a range of cardiovascular diseases, including acute pancreatitis, fatty liver disease, atherosclerosis, and coronary heart disease. In clinical practice, the management of hyperlipidemia is hindered by numerous challenges. One of the critical issues is that traditional lipid-lowering drugs often require long-term or even lifelong administration, potentially inducing a range of adverse effects that compromise patient compliance and therapeutic efficacy. Therefore, there is an urgent need to develop safer and more effective strategies for the prevention and adjunctive treatment of hyperlipidemia with the aim of reducing the risk of disease and over-reliance on medication. Recent studies have revealed a close relationship between hyperlipidemia and related metabolic disorders involving gut microbiota dysbiosis, and the administration of probiotics has been shown to improve lipid metabolism homeostasis. This review summarizes the molecular mechanisms of probiotics in hyperlipidemia treatment and the latest advances in probiotic research on lipid metabolism, enumerates the experimental and clinical applications of probiotic-based therapies, introduces methods for screening and identifying probiotics with lipid-lowering functions, and, for the first time, summarizes the roles of emerging technologies such as functional genomics and in vivo zebrafish-on-a-chip models in studying the lipid-lowering efficacy of probiotics, providing insights for researchers. By facilitating a deeper understanding of the mechanisms whereby probiotics reduce blood lipid levels and furthering the development of multifaceted screening methods, we hope that we can achieve high-throughput and efficient screening of probiotics with lipid-lowering functions, thereby promoting the sustainable, high-quality, and rapid development of the probiotics industry.